-
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
28 May 2024 13:19 GMT
… III trial of AstraZeneca’s Lynparza suspended
AstraZeneca’s Lynparza (olaparib) … is developing the drug candidate for the treatment of severe hypertriglyceridemia … model uses datapoints from individual drugs, clinical trials, regulatory milestones, company, …
-
Tango Stops Early Cancer Trial Over Liver Toxicity, Drops Out of Race Against Roche
23 May 2024 16:03 GMT
… the PARP inhibitor Lynparza (olaparib). However, a safety signal … the pioneering synthetic lethal drug Lynparza.
Early evidence that … Medicine, entered the clinic in August 2023 and the trial … Taylor is a freelance pharmaceutical and biotech writer based in …
-
Discontinue Olaparib Tablets Marketing For Specific Cancers: CDSCO
23 May 2024 22:28 GMT
… Drugs Standard Control Organisation (CDSCO) directed all manufacturers of the anticancer medication Olaparib … be considered inappropriate for endocrine treatment.
AstraZeneca Pharma India Limited … for Olaparib Tablets 100mg and 150mg in the treatment of …
-
Tailoring polymeric micelles for improved olaparib solubility and drug release
23 May 2024 20:27 GMT
… and drug loadings. In addition, the in vitro release of olaparib from … a safe solubilizer for olaparib. In addition, olaparib-loaded micelles had a … and drug conjugation, is needed to improve the retention of olaparib-loaded …
-
Docs support drug regulator’s move to withdraw Olaparib for some cancer patients
23 May 2024 07:55 GMT
… generic drug Olaparib over safety concerns.
Olaparib is a chemotherapy drug and … withdrawn by the US FDA on March 26, so … multiple chemotherapy treatments.
Dr. Shyam Aggarwal, Chairman, Medical Oncology, Sir … and second line of treatment”.
Now Olaparib’s use in …
-
DCGI Orders Withdrawal of AstraZeneca's Cancer Drug Olaparib for...
23 May 2024 07:26 GMT
… 's anti-cancer drug Olaparib tablets for treatment in patients who have … drug to discontinue marketing of Olaparib tablets 100mg and 150mg for the treatment … (CDSCO) approved Olaparib tablets 100mg and 150mg for the treatment of patients …
-
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
23 May 2024 05:12 GMT
… of our medicines in curative-intent lung cancer treatment and … in multiple Phase III trials in this setting, including … is manufactured by AbelZeta Pharmaceuticals Inc. C-CAR031 is … kinase inhibitor, plus Lynparza (olaparib) in patients with platinum-sensitive …
-
DCGI orders withdrawal of AstraZeneca's cancer drug Olaparib for certain treatments
23 May 2024 03:35 GMT
… on overall survival for Olaparib compared to the chemotherapy … withdrawal of indication of Olaparib tablets.
"In … drug under your jurisdiction to withdraw marketing of the product Olaparib … , 2018 for treatment of patients for treatment of adult patients …
-
Tango terminates USP1 inhibitor programme
24 May 2024 11:14 GMT
… ”.
Following the announcement of trial termination, Tango’s stock … polymerase (PARP) inhibitor Lynparza (olaparib) but none of the … by patients in the trial. While disappointing, we … 47;II trials (NCT05275478 and NCT05732831) as a treatment for advanced …
-
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
23 May 2024 22:00 GMT
… Poster: Neoadjuvant combination treatment of olaparib and pembrolizumab for … and Myriad’s two FDA-approved companion diagnostic tests: … and academic or pharmaceutical investigators and is … and guide treatment decisions across medical specialties where …